FINWIRES · TerminalLIVE
FINWIRES

Greatland Resources Posts Lower March Quarter Gold Production; Shares Down 3%

By

Greatland Resources (ASX:GGP) said the March quarter production reached 82,723 ounces of gold and 4,128 tonnes of copper at an all-in sustaining cost (AISC) of AU$2,056 per ounce, according to a Tuesday Australian bourse filing.

The company's December 2025 quarter production was of 86,273 ounces of gold and 3,528 tonnes of copper at an AISC of AU$2,196 per ounce, per the filing.

The company reported sales of 97,800 ounces of gold and 4,620 tonnes of copper at weighted average realized prices of AU$6,773 per ounce and AU$15,803 per tonne, respectively, generating net revenue of AU$742 million.

December 2025 quarter sales were 72,212 ounces of gold and 3,301 tonnes of copper at weighted average realized prices of AU$6,301 per ounce and AU$14,652 per tonne, respectively, generating net revenue of AU$507 million.

Greatland said it expects fiscal 2026 production to be around or slightly above the upper end of its guidance range of 260,000 to 310,000 ounces, with AISC trending toward the lower end of the AU$2,400 to AU$2,800 per ounce guidance range.

Greatland Resources' shares fell 3% in recent Tuesday trade.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA